Pharmaceutical intermediates
Ritlecitinib Intermediates
2 pharmaceutical intermediates for Ritlecitinib. Indication: Alopecia Areata.
About Ritlecitinib
- Originator
- Pfizer Inc
- Indication
- Alopecia Areata
- Approved Date
- 06/23/2023
- NCE Patent
- 06/23/2028
- DS/DP
- 12/03/2034
Available intermediates
2 intermediates currently listed for Ritlecitinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| benzyl (2S,5R)-5-amino-2-methylpiperidine-1-carboxylate hydrochloride | 1207853-23-3 | / | / |
| 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine | 90213-66-4 | / | / |
Other programs under R
Building toward Ritlecitinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →